×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APRE – aprea therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APRE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
08:42 am
apre
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial [Yahoo! Finance]
Low
Report
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial [Yahoo! Finance]
3/31
08:30 am
apre
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
High
Report
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
3/26
08:13 am
apre
Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
3/25
10:08 pm
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
3/25
08:30 am
apre
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Medium
Report
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
3/11
08:30 am
apre
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
Medium
Report
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
2/5
10:24 pm
apre
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics [Yahoo! Finance]
Medium
Report
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics [Yahoo! Finance]
2/5
08:00 am
apre
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
High
Report
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:31 pm
apre
Form 4 Aprea Therapeutics, Inc. For: Mar 27 Filed by: Hamill John P.
Medium
Report
Form 4 Aprea Therapeutics, Inc. For: Mar 27 Filed by: Hamill John P.
3/31
04:30 pm
apre
Form 4 Aprea Therapeutics, Inc. For: Mar 27 Filed by: Gilad Oren
Medium
Report
Form 4 Aprea Therapeutics, Inc. For: Mar 27 Filed by: Gilad Oren
3/25
08:46 am
apre
Form 10-K Aprea Therapeutics, Inc. For: Dec 31
Medium
Report
Form 10-K Aprea Therapeutics, Inc. For: Dec 31
3/25
08:40 am
apre
Form 8-K Aprea Therapeutics, Inc. For: Mar 25
Medium
Report
Form 8-K Aprea Therapeutics, Inc. For: Mar 25
2/13
12:15 pm
apre
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Stonepine Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Stonepine Capital Management, LLC
2/10
12:56 pm
apre
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Sio Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Sio Capital Management, LLC
2/10
08:36 am
apre
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN
Medium
Report
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN
2/5
08:30 am
apre
Form 8-K Aprea Therapeutics, Inc. For: Feb 05
Medium
Report
Form 8-K Aprea Therapeutics, Inc. For: Feb 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/2
Form 3 Aprea Therapeutics, Inc. For: Oct 02 Filed by: Coiante Scott M
32.6%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
TOP News Decliners
3/26
Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus -0.390 ActVsEst (0.250) - Miss
-11.5%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: